Please assess the completion status of the following clinical trial:

Trial Title: A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All patients enrolled in three Phase 3 Janssen-sponsored (C0168T37, C0168T46, C0168T72) infliximab clinical studies in ulcerative colitis that require long-term safety follow-up~* Patients must have received at least 1 dose of study agent to be eligible for participation in the study~Exclusion Criteria:~- Patients who refuse consent or are unwilling to respond to requests for long-term safety information within the required timeframe will be excluded. In addition, patients participating in a study extension to the primary study are not eligible for participation in the C0168T62 study during the study extension participation

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Infliximab 5 mg/kg (Type: None): This is an observational study which includes patients from primary studies C0168T37, C0168T46, C0168T72.
- Infliximab 10 mg/kg (Type: None): This is an observational study which includes patients from primary studies C0168T37, C0168T46, C0168T72.
- Placebo (Type: None): This is an observational study which includes patients from primary studies C0168T37, C0168T46, C0168T72.

Based on this trial design, predict the completion outcome and termination type (if applicable).